Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase

Chronic myelogenous leukemia (CML) is characterized by the oncogenic fusion protein, BCR-ABL protein kinase, against which clinically useful inhibitors have been developed. An alternative approach to treat CML is to degrade the BCR-ABL protein. Recently, potent degraders against BCR-ABL have been de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Shibata, Norihito, Shimokawa, Kenichiro, Nagai, Katsunori, Ohoka, Nobumichi, Hattori, Takayuki, Miyamoto, Naoki, Ujikawa, Osamu, Sameshima, Tomoya, Nara, Hiroshi, Cho, Nobuo, Naito, Mikihiko
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6131351/
https://ncbi.nlm.nih.gov/pubmed/30202081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-31913-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados